PD-1/PD-L1-IN 3 (TFA)

PD-1/PD-L1-IN 3 (TFA)

• UNSPSC Description: PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases[1].
• Target Antigen: PD-1/PD-L1
• Type: Peptides
• Related Pathways: Immunology/Inflammation
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/pd-1-pd-l1-in-3-tfa.html
• Purity: 99.34
• Solubility: H2O : 50 mg/mL (ultrasonic)
• Smiles: OC(C(F)(F)F)=O.O=C(N([C@H](C(N([C@H](C(N[C@H](C(N[C@](CSCC(N[C@H](C(N([C@H](C(N[C@H](C(N1CCC[C@]1(C(N[C@]([H])(C(N[C@H](C(N(CC(N[C@H](C(N[C@H](C2=O)CO)=O)CC3=CNC4=CC=CC=C34)=O)C)=O)CC(C)C)=O)CC5=CN=CN5)=O)[H])=O)CC(N)=O)=O)C)C)=O)CC6=CC=CC=C6)=O)([H])C(NCC(N)=O)=O)=O)CCCNC(N)=N)=O)CCCC)C)=O)CCCC)C)[C@](N2)([H])CC7=CNC8=CC=CC=C78
• Molecular Weight: 1966.19
• References & Citations: [1]MILLER, Michael Matthew, et al. Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions. WO2014151634A1.
• Shipping Conditions: Blue Ice
• Storage Conditions: -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
• Clinical Information: No Development Reported